These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Catechol-O-methyltransferase inhibitors in Parkinson's disease. Henry C; Wilson JA Lancet; 1998 Jun; 351(9120):1965-6. PubMed ID: 9654299 [No Abstract] [Full Text] [Related]
4. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers. Jorga KM Neurology; 1998 May; 50(5 Suppl 5):S31-8. PubMed ID: 9591520 [TBL] [Abstract][Full Text] [Related]
5. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone]. Arnold G; Kupsch A Nervenarzt; 2000 Feb; 71(2):78-83. PubMed ID: 10703007 [TBL] [Abstract][Full Text] [Related]
6. Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease. Sabaté M; Bosch A; Pedrós C; Figueras A Ann Pharmacother; 1999 Nov; 33(11):1228-9. PubMed ID: 10573327 [No Abstract] [Full Text] [Related]
7. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease. Chong DJ; Suchowersky O; Szumlanski C; Weinshilboum RM; Brant R; Campbell NR Clin Neuropharmacol; 2000; 23(3):143-8. PubMed ID: 10895397 [TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies. Jorga K; Fotteler B; Banken L; Snell P; Steimer JL Br J Clin Pharmacol; 2000 Jan; 49(1):39-48. PubMed ID: 10606836 [TBL] [Abstract][Full Text] [Related]
10. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522 [TBL] [Abstract][Full Text] [Related]
11. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group. Hauser RA; Molho E; Shale H; Pedder S; Dorflinger EE Mov Disord; 1998 Jul; 13(4):643-7. PubMed ID: 9686768 [TBL] [Abstract][Full Text] [Related]
12. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group. Waters CH; Kurth M; Bailey P; Shulman LM; LeWitt P; Dorflinger E; Deptula D; Pedder S Neurology; 1998 May; 50(5 Suppl 5):S39-45. PubMed ID: 9591521 [TBL] [Abstract][Full Text] [Related]
13. The disposition of the tolcapone 3-O-methylated metabolite is affected by the route of administration in rats. Funaki T; Onodera H; Ushiyama N; Tsukamoto Y; Tagami C; Fukazawa H; Kuruma I J Pharm Pharmacol; 1994 Jul; 46(7):571-4. PubMed ID: 7996385 [TBL] [Abstract][Full Text] [Related]